Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will
increase the progression-free survival (PFS) in patients with first line metastatic breast
cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with
definable metastatic disease, 6 or more months after primary treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami University of Miami Sylvester Comprehensive Cancer Center